Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 260M 229M 216M 197M 368M 24.97B 371M 2.58B 1B 12.76B 978M 957M 40.99B P/E 2026 *
-17.2x
P/E 2027 * -8.03x
Enterprise Value 260M 229M 216M 197M 368M 24.97B 371M 2.58B 1B 12.76B 978M 957M 40.99B EV / Sales 2026 *
17.1x
EV / Sales 2027 * 15.5x
Free-Float
95.14%
Yield 2026 *
-
Yield 2027 * -
1 day-5.05%
1 week-2.99%
Current month-10.93%
1 month-11.73%
3 months-27.42%
6 months-33.35%
Current year-41.33%
1 week 0.91
Extreme 0.9101
1.05
1 month 0.91
Extreme 0.9101
1.16
Current year 0.91
Extreme 0.9101
1.98
1 year 0.91
Extreme 0.9101
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.71
10 years 0.37
Extreme 0.3651
3.97
Manager TitleAgeSince
Chief Executive Officer 54 2018-09-16
Director of Finance/CFO 50 2022-11-13
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 60 2009-06-30
Director/Board Member 68 2014-04-10
Chairman 60 2024-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/26 Free

Director

125,000 0.0501%
7/1/26
Broadwood Capital, Inc.
FreeCompany 125,000 0.0501%
7/1/26 Free

Director

125,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
-5.05%-2.99%-45.26%-16.26% 260M
+2.64%+6.45%+12.39%+38.40% 47.97B
+0.14%+0.28%+49.75%+36.89% 44.5B
-0.74%+5.80%+342.69%+622.19% 43.93B
+0.92%+0.07%+9.94%+98.68% 41.03B
+0.51%-0.61%+5.18%+46.87% 29.85B
-0.54%-1.63%+22.62%+149.24% 17.27B
-0.04%+9.15%+8.40% - 15.34B
+1.76%+0.85%+29.47%+48.42% 15.3B
+1.75%-3.36% - - 14.82B
Average +0.11%+2.22%+48.35%+128.05% 27.03B
Weighted average by Cap. +0.68%+2.97%+75.88%+164.83%

Financials

2026 *2027 *
Net sales 15.19M 13.33M 12.59M 11.47M 21.48M 1.46B 21.63M 151M 58.36M 744M 57.04M 55.81M 2.39B 16.83M 14.77M 13.95M 12.71M 23.8M 1.61B 23.97M 167M 64.66M 824M 63.21M 61.84M 2.65B
Net income -22.64M -19.87M -18.76M -17.1M -32.01M -2.17B -32.24M -225M -86.97M -1.11B -85.01M -83.17M -3.56B -34.44M -30.22M -28.54M -26.01M -48.69M -3.3B -49.04M -342M -132M -1.69B -129M -127M -5.42B
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
26-09-28 US$0.9749 -5.35% 532,956
26-09-25 US$1.030 +8.67% 2,481,540
26-09-24 US$0.9478 -0.93% 2,439,912
26-09-23 US$0.9567 -8.01% 2,630,848
26-09-22 US$1.040 +2.97% 847,525
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.030USD
Average target price
5.500USD
Spread / Average Target
+433.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock